Latest filing published 03 Jun 2025 for REGENXBIO Inc..
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Daniel Tasse: trading record in brief
Daniel Tasse (board member) discloses dealings in 3 companies, chiefly Bellerophon Therapeutics, Inc., REGENXBIO Inc. and DBV Technologies S.A. The record holds 9 filings, for trades running from 19 February 2015 to 30 May 2025.
Purchases make up the whole of the open-market record (2 purchases, €276k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 7 share grants.
The newest entry dates from 3 June 2025: a share grant, in REGENXBIO Inc. The most recent open-market purchase was published on 11 March 2024, 972 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Daniel Tasse
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,768 shares0Common StockSEC:0001562180-25-004353:0
- 4,790 shares0Common StockSEC:0001562180-24-004650:0
- 17,094 shares@ US$0.83100.0% of flowOrdinary SharesSEC:0001415889-24-007503:0Canonical exit: 6 Jun 2024 (T+90)
- 3,486 shares0Common StockSEC:0001562180-23-004894:0
- 3,010 shares0Common StockSEC:0001562180-22-004881:0
- 11,987 shares0Common StockSEC:0001600132-18-000100:0
- 25,363 shares0Common StockSEC:0001600132-17-000065:0
- 16,356 shares0Common StockSEC:0001600132-16-000041:0
- 25,000 shares@ US$12.00Common StockSEC:0001104659-15-013145:0Canonical exit: 20 May 2015 (T+90)
9 of 9 declarations
